Ninety One North America Inc. Sells 15,015 Shares of Edwards Lifesciences Co. (NYSE:EW)

Ninety One North America Inc. decreased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 4.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 354,003 shares of the medical research company’s stock after selling 15,015 shares during the period. Edwards Lifesciences makes up about 1.6% of Ninety One North America Inc.’s holdings, making the stock its 25th biggest holding. Ninety One North America Inc. owned approximately 0.06% of Edwards Lifesciences worth $26,207,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. FSA Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $30,000. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences during the 3rd quarter valued at $32,000. Avior Wealth Management LLC boosted its position in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares during the period. JFS Wealth Advisors LLC boosted its position in Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after buying an additional 166 shares during the period. Finally, Roble Belko & Company Inc purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $46,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 8,000 shares of company stock valued at $547,430 over the last three months. Insiders own 1.27% of the company’s stock.

Edwards Lifesciences Trading Down 0.5 %

Shares of NYSE EW opened at $71.05 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm’s 50 day moving average price is $72.49 and its 200-day moving average price is $69.73. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a market cap of $41.90 billion, a PE ratio of 10.24, a P/E/G ratio of 3.72 and a beta of 1.11.

Analyst Upgrades and Downgrades

EW has been the subject of several research analyst reports. Citigroup raised their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. The Goldman Sachs Group raised their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Piper Sandler dropped their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Truist Financial reaffirmed a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Finally, Canaccord Genuity Group increased their price target on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research note on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $79.19.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.